SCOLI Logo

Blood Biomarkers for Spine Disease

Research program identifying blood-based biomarkers for degenerative spine disease. Prior work focused on the neural cell adhesion molecule (NCAM) in degenerative cervical myelopathy; current studies at the Veterans Affairs Pittsburgh Healthcare System use a multi-omic approach combining circulating proteins, lipids, and inflammatory markers to guide diagnosis and treatment.

Blood biomarkers for spine disease research
Blood biomarkers for spine disease research

Mission

To identify and validate blood-based biomarkers that track the onset and progression of degenerative spine disease, using a multi-omic approach that combines circulating proteins, lipids, and inflammatory markers to guide treatment decisions and improve patient outcomes.

Research Program Overview

Our biomarker research program investigates how circulating blood markers relate to the onset and progression of degenerative spine disease, including degenerative cervical myelopathy (DCM), a common condition causing spinal cord compression and neurological deficits in older adults.

Prior work in this domain focused on the neural cell adhesion molecule (NCAM) and its relationship to DCM disease stages. Our current work focuses on identifying biomarkers of interest through a multi-omic approach that combines circulating proteins, lipids, and inflammatory markers in the blood. This research is being conducted at the Veterans Affairs Pittsburgh Healthcare System, as Veterans may be at higher risk for degenerative neck disorders.

This approach represents a paradigm shift toward precision medicine in spine care, enabling personalized treatment strategies based on individual biomarker profiles.

Research Impact

Our biomarker research program milestones include:

  • Peer-reviewed publications in spine biomarker research, including a review of biomarkers in degenerative cervical myelopathy and a study of circulating serotonin levels
  • $75,000+ in active research funding — a $50,000 U.S. Department of Veterans Affairs Competitive Career Development Fund (CCDF) award and a $25,000 PuNCH award
  • Clinical Translation focus on developing clinically applicable tests that can guide treatment decisions and improve patient outcomes

Clinical Translation

Our biomarker research focuses on developing clinically applicable tests that can guide treatment decisions and improve patient outcomes. We work toward establishing standardized protocols that can be implemented in routine clinical practice to enhance diagnostic accuracy and personalized treatment planning for spine disease patients.

Primary Research Areas

Multi-Omic Profiling
Integrated analysis of circulating proteins, lipids, and inflammatory markers in the blood to identify biomarkers of degenerative spine disease
Serum Biomarkers
Identification and validation of serum biomarkers for disease stage correlation studies
Inflammatory Markers
Analysis of inflammatory cascade biomarkers and neurodegeneration protein markers
Veteran Spine Health
Biomarker studies conducted at the Veterans Affairs Pittsburgh Healthcare System, as Veterans may be at higher risk for degenerative neck disorders
Treatment Monitoring
Development of biomarkers for treatment response monitoring and precision medicine applications
Clinical Translation
Translation of research findings into clinically applicable diagnostic and treatment tools

Methodology

Our research program utilizes state-of-the-art proteomic, lipidomic, and molecular biology techniques including enzyme-linked immunosorbent assays (ELISA), mass spectrometry, and multiplex protein analysis platforms. We employ rigorous study designs with appropriate controls and statistical power calculations to ensure reliable biomarker discovery and validation. Clinical correlation studies involve comprehensive patient assessment including neurological examination, functional outcome measures, and advanced imaging studies. Longitudinal sample collection protocols enable tracking of biomarker changes over time and correlation with disease progression and treatment responses. We collaborate with clinical laboratories to establish standardized assay protocols for future clinical implementation.

Research inquiries

For collaboration or media inquiries about this program, contact the institute directly.

[email protected]